(C) Epson Le Monde 2017 Faites la transition clip B2BioworldSeiko Epson and its Business Perspectives

June 2017. The Japanese company is awaiting resolute changes in order not to become easy prey for a cheap swap or a takeover. An analysis of business perspectives which includes a discussion of the latest global results as well as in depth figures of European performance, an assessment of geopolitical vulnerabilities, and a look to valuable IP not translated into products. The analysis is complemented by an exclusive face-to-face interview of B2Bioworld with Minoru Usui, CEO of Seiko Epson.

Please note, this article is currently updated. Soon to come.


If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Article free of advertisement
- Includes tables and charts with financial results, (e.g. European revenues 2010/11 to 2015/16) , geographic spread, or key inventions (including upcoming products)

Full Company License enquire here

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Improving the IP System on a global scale: A view from Japan
Moving beyond harmonisation and linking the IP system to R&D policies. Sadao Nagaoka, Institute of Innovation Research, and Chief Policy Adviser to the Japanese Government

Easier Access to Patent Claims Encoded in Chinese
EPO catalyzes innovation of intercontinental IP systems. Questions about Russia’s intentions

The Laboratory Furniture Market
Assessment and Outlook by Tobias Thiele, former Managing Director of Köttermann Group

European and U.S. Codes of Conduct for Development of Robotics and Artificial Intelligence

CO2 as resource for specialty chemicals: What makes it difficult for industry?
Peter Nagler, Head of International Innovation, Evonik Industries anchors the topic in the company’s strategies to internationalise R&D. Nice technological inventions won’t suffice

Yamaha’s Flex-Fuel Criss-Crosser - Brazilian DNA to Re-program Honda Moto
How the Japanese Manufacturer arrived five years too late

Instrument Standards: We need the users, and users have to adopt it
A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing by Oscar-Werner Reif, Member of Board Sartorius Stedim Biotech S.A.

Laboratory Automation: Everyone Re-invents the Wheel
Michael Collasius, Vice President Automated Systems Qiagen NV on industry-wide standards for laboratory instruments

Physics <> Information <> Biology
A view from quantum optics. Interview with Alain Aspect, Professor of Physics at Institut d’Optique and Balzan Prize winner on a core concept in science, interface with biology, and felicity conditions of pluridisciplinary dialogue

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, at the time Chief Technology Officer Life Sciences at Tecan (now at Merck Israel) on strengths and weaknesses of electrowetting, weaknesses of competitors like Illumina, and prospects of clinical microfluidics

Solutions Marketing Never Dreamt of…
David Nicholson, past Head of R&D Bayer CropScience on Hidden Potentials, Revaluation of IP Assets, and Substantial Changes in R&D

Resolving the Innovation Paradox
Günter von Au, Vice-Chairman of the Board,, Clariant AG

Printable matrices for bioprinting applications